schizophrenia
NICE decides to back Abilify in schizophrenia
January 27, 2011Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia
NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …
Janssen’s Invega wins schizoaffective approval in Europe
January 6, 2011Sales and Marketing Invega, Janssen, paliperidone ER, schizoaffective disorder, schizophrenia
Janssen’s Invega has become the first drug to be licensed in Europe to treat schizoaffective disorder. European regulators approved Invega …
Roche highlights R&D promise after setbacks
December 9, 2010Research and Development MS, Roche, oncology, personalised medicine, schizophrenia
Roche has presented its pipeline to shareholders to boost confidence that it can sustain the spectacular growth of recent years. …
NICE issues schizophrenia commissioning guide
January 14, 2010NICE, commissioning, schizophrenia
NICE has published a commissioning guide to help primary and secondary care teams recognise, treat and manage adult schizophrenia. The …
The management of schizophrenia
October 14, 2003Sales and Marketing NICE, clinical guidelines, healthcare, schizophrenia
The publication of NICE's clinical guidelines on the management of schizophrenia in December marks a significant milestone – the first …
Latest content
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
